zanubrutinib

Sponsor Beone Medicines LTD. · listed as ONC

READOUT Phase 3 Confidence: medium Source: clinicaltrials

zanubrutinib is a clinical-stage drug asset sponsored by Beone Medicines LTD., listed as ONC. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Mar 2027 (month precision, medium confidence), tied to trial NCT04002297. The asset is in Phase 3 and currently active not recruiting, studied in Mantle Cell Lymphoma. It appears across 9 tracked trials in the CSA sample.

Next catalyst

Event typeREADOUT

Expected date2027-03-31

As disclosedMar 2027

Date precisionmonth

Confidencemedium

Verify at source →

Trial & sponsor

Trial (NCT)NCT04002297

PhasePHASE3

StatusACTIVE_NOT_RECRUITING

Lead sponsorBeOne Medicines

Listed asONC

Condition(s)Mantle Cell Lymphoma; Non-Hodgkin Lymphoma

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.

Get the full dataset — $499 → More ONC catalysts